Found: 14
Select item for more details and to access through your institution.
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products—a Meeting Report.
- Published in:
- AAPS Journal, 2024, v. 26, n. 1, p. 1, doi. 10.1208/s12248-023-00884-5
- By:
- Publication type:
- Article
Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
- Published in:
- AAPS Journal, 2019, v. 21, n. 5, p. N.PAG, doi. 10.1208/s12248-019-0363-5
- By:
- Publication type:
- Article
A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
- Published in:
- AAPS Journal, 2016, v. 18, n. 1, p. 228, doi. 10.1208/s12248-015-9836-3
- By:
- Publication type:
- Article
Approval of Mycophenolate Mofetil for Prophylaxis of Organ Rejection in Pediatric Recipients of Heart or Liver Transplants: A Regulatory Perspective.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 3, p. 807, doi. 10.1002/cpt.3288
- By:
- Publication type:
- Article
Model‐Informed Drug Development Approaches to Assist New Drug Development in the COVID‐19 Pandemic.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 3, p. 572, doi. 10.1002/cpt.2491
- By:
- Publication type:
- Article
Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 4, p. 259, doi. 10.1002/psp4.12287
- By:
- Publication type:
- Article
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2021, v. 48, n. 1, p. 55, doi. 10.1007/s10928-020-09718-9
- By:
- Publication type:
- Article
Model‐Informed Approaches to Support Drug Development for Patients With Obesity: A Regulatory Perspective.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, p. S65, doi. 10.1002/jcph.2349
- By:
- Publication type:
- Article
Model‐Informed Approach Supporting Drug Development and Regulatory Evaluation for Rare Diseases.
- Published in:
- Journal of Clinical Pharmacology, 2022, v. 62, p. S27, doi. 10.1002/jcph.2143
- By:
- Publication type:
- Article
Model‐Informed Drug Development in Pediatric Dose Selection.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, p. S60, doi. 10.1002/jcph.1848
- By:
- Publication type:
- Article
Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, p. S104, doi. 10.1002/jcph.1478
- By:
- Publication type:
- Article
Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, p. S104, doi. 10.1002/jcph.1478
- By:
- Publication type:
- Article
Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
- Published in:
- Oncologist, 2018, v. 23, n. 4, p. 496, doi. 10.1634/theoncologist.2017-0422
- By:
- Publication type:
- Article